Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=63 Raloxifene and Rimostil for Perimenopause-Related Depression
Perimenopausal Depression · Depression
Primary: Center for Epidemiologic Studies-Depression Scale (CES-D) — 27.4; 29.1; 28.8; 24.6 Units on a scale
Phase 2 N=133 Homeopathic Treatment for Depression in Peri- and Postmenopausal Women
Moderate Depression · Menopausal and Postmenopausal Disorders
Primary: Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks. — 9.9; 11.7; 15 Units in Hamilton Scale — p=<0.05
N/A N=24 Omega-3 for Peri- and Postmenopausal Depression
Depression
Primary: Change in MADRS Score — 12.0 units on a scale
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Phase 4 N=64 Perimenopausal Effects of Estradiol on Reward Responsiveness
Perimenopausal Depression
Primary: Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment — .027; .043 percent signal change — p=.620
Phase 4 N=47 Vortioxetine for Menopausal Depression
Depression · Menopause · Vasomotor Disturbance
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5) — -22.8 units on a scale
Phase 2 N=73 A Neurosteroid Intervention for Menopausal and Perimenopausal Depression
Major Depressive Disorder · Menopause · Perimenopause
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 26.2; 27.0; 15.7; 15.2 units on a scale — p=0.29
Phase 4 N=30 Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score — -.05; .35 units on a scale — p=.012
Phase 4 N=46 Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Cyclical Change in Suicidal Ideation (SI) Severity — -.22; -.05; .25 units on a scale — p=.002
Phase 4 N=20 Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"
Perimenopausal Disorder · Depression
Primary: Change in Frontostriatal Reactivity to Reward During MID fMRI Task — .0704; .0475; .0623; .0280 percent signal change — p=0.53
Phase 4 N=22 Duloxetine for Menopausal Depression
Depression · Menopause · Vasomotor Symptoms
Primary: Change in Depression Scores as Measured by the Hamilton Rating Scale for Depression — -7.5 units on a scale
N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 2 N=46 Estrogen Receptor Beta and Mood
Perimenopause-Related Depression
Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale
N/A N=36 Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition
Postpartum Depression
Primary: Blood-oxygen-level-dependent (BOLD) Response During Functional Magnetic Resonance Imaging (fMRI) z Statistic — 2.3; 2.0; 2.1; 1.7 z score — p=.27
N/A N=9 Effects of Testosterone in Women With Depression
Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Scale — 25.9; 14.7; 15.2 units on a scale — p=0.002
Phase 1 N=29 Development of Pregnenolone as a Treatment for Depression
Major Depressive Disorder
Primary: Amygdala-PCC Functional Connectivity — -0.0815; -0.0530; -0.0456 z-score — p=.195
N/A N=32 The Oral Contraceptive Pill for Premenstrual Worsening of Depression
Premenstrual Syndrome · Depression
Primary: Percent Change in Luteal Montgomery-Asberg Depression Rating Scale (MADRS) — -43.6; -38.9 percent change — p=.59
Phase 4 N=124 Cyclical Neuroactive Steroid Changes, Arousal, and Proximal Suicide Risk: An Experimental Approach
Suicidal Ideation
Primary: Perimenstrual Change in Daily Adult Suicidal Ideation Questionnaire (ASIQ) Scores — .178; -.051 Mean Score Change — p=<.001
N/A N=42 Mommy-Baby Treatment for Perinatal Depression
Depressive Disorder, Major · Postpartum Depression
Primary: Change in Edinburgh Depression Scale From Baseline — 17.81; 17.9; 12.04; 11.41 units on a scale
N/A N=41 Self-Management of Chronic Depressive Symptoms in Pregnancy
Depression
Primary: Recruitment Data — 41 Participants
Phase 4 N=18 Brain Imaging Study in Menopausal Women With and Without Major Depressive Disorder
Menopause · Depression
Primary: Comparison of Cortical GABA Levels in 4 Groups of Subjects Using Estrogen Alone, Fluoxetine Alone, Estrogen and Fluoxetine Combined in Pre and Post 4.0T Magnetic…
Phase 1 N=40 Sleep and Healthy Aging Research on Depression for Younger Women
Anhedonia · Depression
Primary: Non-social (Monetary) Reward Response (Reward Learning and Sensitivity) — .563; .307; .309; .366 response bias — p=.16
Phase 4 N=439 Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)
Major Depressive Disorder
Primary: Change From Baseline in Hamilton Depression Scale (HAM-D17) at Week 8 — 22.8; 22.4; -9.7; -7.4 Units on a scale — p=0.004
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=47 Estrogen and Serotonin on Changing Brain Chemistry
Menopause
Primary: Percent Change in BOLD Signal — -.43; .20 percentage of BOLD signal changes
Phase 3 N=381 Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8. — -12.64; -8.33 units on scale — p=<0.001
Phase 4 N=84 Stress & Premenstrual Symptoms Study
PMDD · Stress · Mood
Primary: Acoustic Startle Response (ASR) Magnitude Based on Menstrual Cycle Phase — 54.2; 53.7; 56.4; 53.3 t score — p=0.139
N/A N=30 Early Menopause Hormone Treatment and Cognition
Menopausal Syndrome
Primary: Changes in Brain Activation Patterns in Verbal Tasks Determined With the Functional Magnetic Resonance Imaging (fMRI) Scans — .14; .13; .05; .13 percent BOLD signal…